ArticleCureus2025
Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) in Patients With Acromegaly in Colombia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Distinct sleep-disordered breathing phenotypes in elderly patients with depressive disorder: links to hypoxemia severity and inflammatory burden.Frontiers in psychiatry · 2026Article
- Polysomnographic Analysis in Snoring Patients.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Acromegaly is a rare, chronic, and progressive disorder characterized by excessive secretion of growth hormone (GH) after the closure of the epiphyseal plates. The disease has an estimated annual incidence of 5 cases per 1,100,000 individuals. Sleep apnea/hypopnea syndrome (OSAHS) affects up to 80% of individuals with acromegaly and is recognized as an independent risk factor for the development of cardiovascular disease. This study aims to estimate the prevalence of SAHS and its associated factors in patients with acromegaly in Colombia. Methods This observational, retrospective cohort study utilized the National Registry of Patients with Acromegaly (RAPACO) data. The study evaluated patients who had undergone baseline polysomnography as a criterion for inclusion. Results A total of 163 patients were included in the study, of whom 89 (54.6%) were diagnosed with OSAHS. Women accounted for 99 (60.7%) of the cohort, aged 34.4 to 63.54 years. Patients with OSAHS exhibited a higher BMI and a longer disease duration. Additionally, they demonstrated elevated levels of IGF-1 (936.2 ± 447.2) and baseline GH (20.0 ± 20.4), both of which were statistically significant (p = 0.006 and p = 0.027, respectively). Severe apnea was the most prevalent form of the condition, and microadenoma was the predominant tumor type. Multivariate analysis identified disease duration and IGF-1 levels as the primary variables associated with OSAHS. Conclusion OSAHS is a prevalent comorbidity in patients with acromegaly, with hormonal factors playing a critical role in its pathogenesis. Consistent with previous studies, our findings demonstrate that elevated IGF-1 and GH levels are associated with greater OSAHS severity. Routine polysomnography (PSG) is recommended following the diagnosis of acromegaly. If OSAHS is confirmed, appropriate treatment should be initiated, and follow-up PSG should be performed during acromegaly management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.